TARO PHARMACEUTICAL INDUSTRIES LTD Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q4 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Mar 31, 2012	Q3 FY2012 As of Dec 31, 2011
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Restricted short-term bank deposits
Short-term bank deposits
Short-term and current maturities of long-term bank deposits
Marketable securities

Accounts receivable and other:
Trade, net
Other receivables and prepaid expenses
Inventories
Long-term assets held for sale, net
TOTAL CURRENT ASSETS

LONG-TERM RECEIVABLES AND OTHER ASSETS
LONG-TERM RECEIVABLES AND OTHER ASSETS
LONG-TERM BANK DEPOSITS
LONG-TERM DEPOSITS AND MARKETABLE SECURITIES
LONG-TERM MARKETABLE SECURITIES
PROPERTY, PLANT AND EQUIPMENT, NET
DEFERRED INCOME TAXES
GOODWILL
INTANGIBLE ASSETS AND DEFERRED COSTS, NET
OTHER ASSETS
TOTAL ASSETS

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Short-term bank credit and short-term loans
Current maturities of long-term debt
Accounts payable:
Trade payables
Settlement and loss contingencies
Returns reserve
Accrued income taxes
Accrued expenses
Employees and payroll accruals
Medicaid and indirect rebates
Other current liabilities
TOTAL CURRENT LIABILITIES

LONG-TERM LIABILITIES:
Long-term debt, net of current maturities
Deferred income taxes
Other long-term liabilities
TOTAL LONG-TERM LIABILITIES

TOTAL LIABILITIES
SHAREHOLDERS’ EQUITY:
Taro shareholders' equity:
Ordinary shares of NIS 0.0001 par value: Authorized at March 31, 2012 and December 31, 2011: 200,000,000 shares; Issued at March 31, 2012 and December 31, 2011: 44,800,007 and 44,799,507 shares, respectively; Outstanding at March 31, 2012 and December 31, 2011: 44,476,532 and 44,476,032 shares, respectively
Ordinary shares of NIS 0.0001 par value: Authorized at March 31, 2023 and March 31, 2022: 200,000,000 shares; Issued at March 31, 2023 and March 31, 2022: 45,116,262 shares Outstanding at March 31, 2023 and March 31, 2022: 37,584,631 shares
Founders' shares of NIS 0.00001 par value: Authorized, issued and outstanding at March 31, 2023 and March 31, 2022:2,600 shares
Additional paid-in capital
Accumulated other comprehensive loss, net of taxes
Treasury stock at March 31, 2023 and March 31, 2022: 7,531,631 shares
Accumulated earnings
Taro shareholders' equity

Non-controlling interest
TOTAL SHAREHOLDERS’ EQUITY
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

Comments